FindTrial
Sign In

A Study to Evaluate the Effectiveness and Side Effects of Modern Radiotherapy in Oropharyngeal Cancer Patients.

Tumor response and toxicities of volumetric modulated ARC radiotherapy in oropharyngeal carcinoma - prospective observational study - ARC-ORO Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106626
Enrollment
100
Registered
2026-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: C108- Malignant neoplasm of overlappingsites of oropharynx

Interventions

Intervention1: Nil: Nil

Sponsors

SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Biopsy proven squamous cell carcinoma [SCC] of Oropharynx 2. Patient with american Joint Committee on Cancer [AJCC] Clinical stage I IVB (HPV negative), stage I - III (HPV positive) oropharyngeal cancer. 3. Patients with eastern cooperative oncology group [ECOG] performance status of 0-2.

Exclusion criteria

Exclusion criteria: 1. Patient with distant metastasis. 2. Patient with ECOG performance status of 3-4. 3. Patients who have undergone prior surgery to Head and neck region. 4. Patients previously treated with prior radiotherapy to head & neck region. 5. Pregnant and lactating mothers.

Design outcomes

Primary

MeasureTime frame
To estimate Tumor ResponseTimepoint: 3 months—

Secondary

MeasureTime frame
To evaluate the acute, late toxicities & survival.Timepoint: Acute toxicities- from start of treatment to 3 months late toxicities- after 3 months of radiotherapy—

Countries

India

Contacts

Public ContactDr B SREENIVASA RAO

SRI VENKATESHWARA INSTITUE OF MEDICAL SCIENCES

doctorrt12@gmail.com9701951615

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026